Bjarne Sørensen is a director of front-end innovation at Phillips Medisize, based in the company’s development centre in Denmark. With more than 35 years of experience within product, strategy, and business development, Bjarne has a very visible track record within different business areas. At Phillips Medisize, he participates in customer projects, typically involving electronic injectors and connected health systems. He is also deeply involved in new electronic platform programs, especially on conceptual, technical, and sustainability aspects.

Claus studied pharmacy and holds a PhD (University of Freiburg, Germany) and MBA (Henley Business School, UK). He is Qualified Person according to EU Regulations and holder of various expert qualifications.

For more than 30 years he worked for top ten global pharma companies Roche and Sanofi. He has held various roles in the field of injectable drug delivery systems for biotherapeutics, the first disposable pen for a once-daily insulin, with expanding responsibilities: QA/QC, Manufacturing, Supply Chain, Key Account Management of device partner companies, Global Medical Device Surveillance. As Global Device Leader and Drug Device Integrator he has set up cross-functional technology teams on 'Large Volume Drug Delivery' which has become the On-Body Delivery platform for Drug Device Combination developments like the subcutaneous administration of isatuximab (Sarclisa®).

Since October 2024 Claus is an Independent Drug Device Expert to provide guidance and expertise on complex injectable Drug Device combination products with special focus on integrating medical devices and large volume, highly viscous drug formulations as well as connectivity and sustainability.

Mehul Desai, PharmD, MBA, has vast experience in medical and clinical affairs across the pharmaceutical space. At Enable Injections, he leads medical and clinical programming to support publication, new partnerships, and regulatory approvals. Prior to Enable Injections, Mehul served as Associate Medical Director for argenx, driving the strategic direction, supporting clinical trial execution, and contributing to business development activities across various therapeutic areas. Previous experience includes field medical assignments in rare disease, nephrology, and neurology for Mallinckrodt Pharmaceuticals, nephrology and hematology for Alexion Pharmaceuticals, and post-doctoral fellowship work in Medical Affairs for Johnson & Johnson. Mehul also served as a clinical instructor of Pharmacy Practice and Pharmacy Administration at the University of the Sciences in Philadelphia.

Mehul is a published author in peer-reviewed journals, focusing on drug formulation and on-body delivery systems. He regularly delivers podium presentations at industry conferences, contributing to scientific discussions on novel drug delivery technologies.

Mehul holds a bachelor’s degree in Biochemistry and Business Foundations from Indiana University, Bloomington, a Doctor of Pharmacy from Purdue University, and a Master of Business Administration in Pharmaceutical and Healthcare Business from the University of the Sciences in Philadelphia.